Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials
Date:11/12/2013

in the outcome of this clinical program, and we believe the market opportunities continue to expand for a novel Schedule 3 opioid like buprenorphine."

"Finally, with our BUNAVAIL clinical program complete and our BEMA Buprenorphine chronic pain program winding down, we anticipate that our research and development spending for the remainder of 2013 and for 2014 will be reduced substantially.  This spending reduction, along with the guaranteed Endo milestones, will give us sufficient cash runway to reach BUNAVAIL revenue, which would be expected in the third quarter of 2014 assuming a June 2014 approval.  This would leave us cash flow positive at the end of 2014.  Needless to say, we have a very exciting 12 months in front of us with some very important catalysts," concluded Dr. Sirgo.

Anticipated 2013/2014 Milestones

BDSI is focusing its resources on achievement of the following key milestones:

  • BUNAVAIL NDA. Based on timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the BUNAVAIL NDA is expected to be completed by June 7, 2014.
  • Milestone Payments and Phase 3 study results for BEMA Buprenorphine.  BDSI and Endo expect data from the opioid naive Phase 3 study to report out in early-2014 with the opioid experienced trial to report out in mid-2014.  Upon completion of study enrollment and database lock for each trial and the acceptance of filing of the NDA with the FDA, BDSI is expected to receive milestone payments from Endo totaling $30 million. 
  • Initiation of Confirmatory Phase 2B Study for Clonidine Topical Gel.  BDSI plans to initiate a Phase 2B study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy in the first quarter of 2014.   This study could complete in 2014.

About BioDelivery Sciences International

BioDelivery Sciences Inte
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
2. Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
4. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
5. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
6. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
7. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
8. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
9. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
10. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
11. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Pieris AG presented the results ... most advanced Anticalin ® , PRS-050, an anti-VEGF ... Conference held in San Francisco, California.  The dose-escalation ... tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... for the third quarter ended September 30, 2011. ... revenues were RMB124.7 million ($19.6 million)(A) in the third quarter ...
Cached Medicine Technology:Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 2Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 3Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15
(Date:7/26/2014)... Studio B Dental in Toronto now offers All-on-Four dental ... a Day, gives patients the opportunity to replace their damaged ... whites with very little recovery time and no bone grafting. ... like natural teeth, and require no special care beyond the ... is one of the premiere dental experts on All-on-Four implants ...
(Date:7/26/2014)... According to the Banish My Bumps Pdf review ... that covers detailed instructions on how to eliminate ... any medication. , Vkool reveals in its review ... for relieving symptoms of keratosis pilaris quickly. In addition, ...     How to treat children's keratosis pilaris ,     How ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 PersonalInjurySolicitorsIreland, ... legal help to people who have suffered from ... launch of both their new company, and a ... on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , ... The focus of the company is always on ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 American ... accidents or unexpected collisions can pay higher premiums for ... enhanced its local insurer network to provide SR22 insurance ... . , The different coverage network of local ... has expanded the search platform now publicly available for ...
(Date:7/25/2014)... Ohio (PRWEB) July 25, 2014 Consuming ... foods? How to know? , Read the labels! , ... and determine how it relates to health during a ... p.m. Aug. 1 at Humility House, 755 Ohltown Road, ... will lead an informational discussion and answer questions. ...
Breaking Medicine News(10 mins):Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Learn to Decipher Food Labels at Humility House 2
... had developed new technology to use transistors in devices ... ,The biosensor technology was developed by a ... Science and Technology. ,"We proved that transistors ... for devices that convert biological responses into electrical signals," ...
... First Lady of the United States, Laura Bush arrived in the ... Africa tour to bolster the US government's anti AIDS and malaria ... President Abdoulaye Wade's wife Viviane. ,From Senegal she is ... a five-day long trip to the continent which will also focus ...
... study published on bmj.com today (Tuesday 26 June) ... patients with well-controlled, non-insulin dependent (type 2) diabetes. ... the American Diabetes Association Conference, suggests that current ... reviewed. ,Non-insulin dependent (type 2) diabetes ...
... observed as the National Testing Day in the US. ... produced by the National Association of People with AIDS ... HIV counseling and testing. ,The Centers for ... 280,000 people nationwide are HIV-positive but are unaware of ...
... celebrating annual Monsoon festival, which marks San Joao, the feast ... a legacy Goans have inherited from the Portuguese, who ruled ... ,During the celebrations, Goans jumped into rivers, ponds and wells ... celebrated with much traditional fervour. ,At Loutulim in ...
... for Evolutionary Anthropology, Leipzig, Germany, have investigated evidence of ... about altruism are often based on the assumption that ... human version differs from that of other animals in ... colleagues have found evidence that chimpanzees act altruistically toward ...
Cached Medicine News:Health News:Questions Over Value of Glucose Monitoring for Non-insulin Using Diabetes Patients 2Health News:US Officials Urge Testing for HIV as Health Crisis Intensifies 2Health News:US Officials Urge Testing for HIV as Health Crisis Intensifies 3Health News:Goans Celebrate Monsoon Festival 2